Literature DB >> 30197973

Inequality in Care and Differences in Outcome Following Stroke in People With ESRD.

Mark D Findlay1,2, Jesse Dawson1,2, Rachael MacIsaac1, Alan G Jardine1,2, Mary Joan MacLeod3, Wendy Metcalfe4, Jamie P Traynor2, Patrick B Mark1,2.   

Abstract

INTRODUCTION: Stroke rate and mortality are greater in individuals with end-stage renal disease (ESRD) than in those without ESRD. We examined discrepancies in stroke care in ESRD patients and their influence on mortality.
METHODS: This is a national record linkage cohort study of hospitalized stroke individuals from 2005 to 2013. Presentation, measures of care quality (admission to stroke unit, swallow assessment, antithrombotics, or thrombolysis use), and outcomes were compared in those with and without ESRD after propensity score matching (PSM). We examined the effect of being admitted to a stroke unit on survival using Kaplan-Meier and Cox survival analyses.
RESULTS: A total of 8757 individuals with ESRD and 61,367 individuals with stroke were identified. ESRD patients (n =486) experienced stroke over 34,551.9 patient-years of follow-up; incidence rates were 25.3 (dialysis) and 4.5 (kidney transplant)/1000 patient-years. After PSM, dialysis patients were less likely to be functionally independent (61.4% vs. 77.7%; P < 0.0001) before stroke, less frequently admitted to stroke units (64.6% vs. 79.6%; P < 0.001), or to receive aspirin (75.3% vs. 83.2%; P = 0.01) than non-ESRD stroke patients. There were no significant differences in management of kidney transplantation patients. Stroke with ESRD was associated with a higher death rate during admission (dialysis 22.9% vs.14.4%, P = 0.002; transplantation: 19.6% vs. 9.3%; P = 0.034). Managing ESRD patients in a stroke unit was associated with a lower risk of death at follow-up (hazard ratio: 0.68; 95% confidence interval: 0.55-0.84).
CONCLUSION: Stroke incidence is high in ESRD. Individuals on dialysis are functionally more dependent before stroke and less frequently receive optimal stroke care. After a stroke, death is more likely in ESRD patients. Acute stroke unit care may be associated with lower mortality.

Entities:  

Keywords:  ESRD; dialysis; stroke; transplantation outcomes

Year:  2018        PMID: 30197973      PMCID: PMC6127409          DOI: 10.1016/j.ekir.2018.04.011

Source DB:  PubMed          Journal:  Kidney Int Rep        ISSN: 2468-0249


Declining kidney function is associated with increased cardiovascular risk, and the presence of chronic kidney disease (CKD) is incorporated into risk prediction algorithms used to guide preventative treatments for cardiovascular disease.2, 3 Risk is greatest in end-stage renal disease (ESRD), which is approximately 5 to 20 times that of the age-matched controlled general population,4, 5 and treatments such as dialysis or immunosuppression for kidney transplantation may increase risk further.6, 7 Risk of stroke is reported to be 10 time more common in ESRD,8, 9 yet case mix presentation, management, and outcomes of stroke in individuals with ESRD remains poorly understood. In ESRD, provision of evidence-based management of cardiovascular disease and stroke prevention is hindered10, 11, 12 by limited evidence of benefit with interventions such as statins or anticoagulation. Advanced CKD is a common exclusion criterion in trials that target cardiovascular risk. Individuals with ESRD are typically admitted to renal units when hospitalized for intercurrent illness.10, 16 This could affect access to stroke unit care and treatments shown to improve stroke outcomes. We assessed the incidence of stroke in ESRD and if the presence of ESRD influenced presentation, management, and outcome of stroke by merging data from the Scottish Renal Registry and Scottish Stroke Care Audit. We hypothesized that key care quality indicators in stroke would be less commonly achieved in those with ESRD compared with those without ESRD.

Methods

We performed a national data linkage study using data within the Scottish Renal Registry (SRR), Scottish Stroke Care Audit (SSCA), Scottish Morbidity Records (SMR), and the National Records of Scotland. We used propensity score matching (PSM) and assessed case mix presentation, measures of care quality, and outcomes after stroke in individuals with and without ESRD.

Data Sets

SRR is a nation-wide data set, contributed to by all renal units in Scotland.18, 19 All patients who receive renal replacement therapy (RRT) for ESRD are included. The SRR records patient demographics, renal replacement modality, clinical measurements, laboratory results, and cause of death. SSCA monitors performance of stroke care against guideline-derived standards throughout Scotland. Data held by the SSCA includes all cases of stroke and transient ischemic attack admitted to hospital. Ascertainment of stroke cases in the SSCA is carried out by trained audit coordinators supported by stroke clinicians. Data are collected on demographics, case mix at presentation, stroke classification, use of brain imaging, antithrombotic medication, stroke unit care, and discharge outcomes. This data set has provided coverage of all hospitals managing acute stroke since 2005. SMR01 has been collecting data on all surgical and medical hospital admissions since 1968. Since 1989, SMR01 has been used to plan hospital finances to ensure a high completion rate. The National Records of Scotland is a department of Scottish Government, responsible for registration of life events, including deaths. All 4 datasets were linked, from January 1, 2005 to December 31, 2013. We included only adults (16 years or older at stroke) in our analyses. Supplementary Figures S1 and S2 demonstrate the construction of the linked data sets for analysis.

Definitions

Stroke

Only cases of confirmed stroke as a final diagnosis were included. The SMR01 was interrogated for International Classification of Diseases (ICD-10) codes for stroke (I60, I61, I62.9, I63, and I64). All stroke diagnoses were ordered by date of stroke from January 1, 2005 and the first recorded stroke date, with the source of diagnosis recorded. In cases in which SMR01 and SSCA diagnoses overlapped, the SSCA was used as the source.

End-Stage Renal Disease

All patients commencing RRT for ESRD in Scotland are recorded within the SRR. ESRD is a diagnosis determined by the clinician initiating RRT or by continued use of RRT for >90 days for acute kidney injury without renal recovery.

Modality of RRT

We considered 3 groups of ESRD patients; (i) all patients with ESRD regardless of RRT modality, (ii) patients receiving dialysis (either hemodialysis [HD] or peritoneal dialysis [PD] at the start of study, or who began HD or PD as their first RRT modality during the study), and (iii) individuals with a kidney transplant (either at commencement of the study or who were transplanted during the study de novo or after a period of dialysis).

Baseline Characteristics

The SMR01 was interrogated from January 1, 1981 to December 31, 2013 for presence of ICD-10 codes related to atrial fibrillation and/or flutter (I48), ischemic heart disease (I21, 24, 24.8, I24.9, I25, I25.1, I25.2, I25.5, and I25.8), diabetes mellitus (E10 and E11), and hypertension (I10 and I15). To prevent overlap of diagnoses, ICD codes for stroke (as previously described) were pulled from 1981 until date of the first stroke in individuals who experienced stroke or until December 31, 2013 in individuals who did not have a stroke. Using Scottish Government urban-rural and socioeconomic classifications based on patient postcode, we subdivided patients into the most or least deprived and urban or rural as described elsewhere. We used the postcode at commencing RRT in patients on RRT or with stroke for the non-ESRD stroke population.

SSCA Auditable Standards

SSCA annually reports standards of stroke care compared with audited targets, specifically, the percentage with access to a stroke unit within 1 day of admission, brain imaging within 24 hours of admission, swallow screen on day of admission, aspirin within 1 day of admission (if the index stroke was ischemic), and thrombolysis within 1 hour of arrival to hospital. We present 2 forms of data regarding these standards. First, the percentage of cases that received the following at any point during their admission included stroke unit care, brain imaging, swallow screen, aspirin, or thrombolysis. Second, we reanalyzed, using date and time of admission to hospital and date and time of each care standard, to determine time-specific outcomes as per SSCA standards.

Mortality

Using the national death records, we determined vitality status until September 25, 2015 for all persons. Death during stroke admission and vitality status at end of follow-up are presented. When exploring the impact of stroke care on mortality, we omitted cases of stroke diagnosed only at death and analyzed both ESRD and non-ESRD populations based on the source of the initial diagnosis: SSCA or SMR01. Causes of death for all patients are presented as per ICD-10 coding rules in Supplementary Tables S1 to S3.

Statistical Analyses

Data cleaning and analyses were performed using SAS, version 9.4 (SAS Institute Inc, Cary, NC). Graphs were produced using Stata version 14.1 (Statacorp, College Station, TX). Incidence rates are expressed per 1000 patient-years and calculated using the number of stroke events divided by the follow-up time. Follow-up time is calculated using date of study entry (January 1, 2005) or start of RRT for ESRD until the date of stroke, death, change of renal replacement modality, or end of study. We compared patient demographics split by the source of stroke diagnosis: SSCA versus SMR01 and stroke versus no stroke. Demographic values are presented as mean ± SD or median (interquartile range [IQR]), and comparison between groups was assessed using the t-test, Mann-Whitney U test, or the χ2 test as appropriate. To account for differences in cohort size, we compared pre- and postmatching demographics using standardized differences.

Propensity Score Matching

Individuals with ESRD and stroke are more likely to have comorbidities than individuals without. To reduce the potential for confounding, we performed propensity score matching (PSM) for all ESRD patients, then individually for each of those on dialysis and with a renal transplant. Matching was based on factors predictive of stroke or outcome. Specifically, we matched on age, sex, deprivation and rurality status, and medical history of stroke, ischemic heart disease, hypertension, diabetes, and atrial fibrillation. We matched using nearest neighbour matching, at a ratio of 5:1. Data were tabulated for all ESRD, dialysis, and kidney transplantation cohorts. Data were presented before and after PSM in each case, with comparison between groups using the Mann-Whitney U or the χ2 tests as appropriate. Because our primary aim was to directly compare cohorts, missing data were not imputed, but rather were presented within each table. PSM was performed using the computing environment R, MatchIt package (R Foundation, Vienna, Austria). Survival analyses were performed using the Kaplan-Meier estimator and Cox proportional hazard model. We assessed differences between survival probabilities after stroke in dialysis, kidney transplantation, and non-ESRD stroke populations. Finally, to explore effects of care on outcome, we used admission to a stroke unit as a surrogate for optimal stroke care in ESRD (adjusted for age, sex, use of dialysis, previous diabetes, ischemic heart disease, hypertension, and atrial fibrillation) to examine its impact on death at follow-up. The strengthening the reporting of observational studies in epidemiology (STROBE) guidelines were followed in this observational study (Supplementary Figure 4).

Ethical Approval

The data sets used work within the National Health Service Code of Practice on Protecting Patient Confidentiality, incorporating requirements of statutes and common law including the Data Protection, Human Rights, and the Adults with Incapacity (Scotland) Acts. Access and use of data were approved following National Services Scotland proportionate governance review by the Privacy Advisory Committee of Information Services Division, National Health Service Scotland Reference 55/14.

Results

ESRD Stroke Incidence Rate and Stroke Record Source

There were 8757 individuals aged 16 or older in the SRR from January 1, 2005 to December 31, 2013. A total of 6749 were receiving dialysis at study entry, and 3699 had a kidney transplant at entry or were transplanted during follow-up. A total of 486 (5.5%) individuals experienced stroke during 34,551.9 patient-years of follow-up. The stroke incidence rate per 1000 patient-years for all individuals with ESRD was 14.1; for individuals on dialysis, it was 25.3 (26.7 for HD and 17.3 for PD), and for individuals with a kidney transplant, it was 4.5. Of the first recorded stroke during the study period, 230 (47.3%) were recorded in the SSCA, 219 (45.1%) in the SMR01, and 37 (7.6%) as a primary cause of death (having not been diagnosed prior to death). No significant differences existed in baseline demographics between individuals with ESRD and stroke in the SMR01 database compared with the those in the SSCA database (Table 1).
Table 1

Baseline demographics of all end-stage renal disease patients with stroke, split by source of diagnosis

VariableSSCA stroke (n = 230)SMR01 stroke (n = 219)P value
Age at stroke, yr, median (IQR)71 (13)71 (17)0.406
Sex
 Female (%)111 (48.3)93 (42.5)
 Male (%)119 (51.7)126 (57.5)0.220
Primary renal diagnosis group
 Glomerulonephritis36 (15.7)31 (14.2)0.692
 Interstitial disease48 (20.9)46 (21.0)1.000
 Multisystem53 (23.0)46 (21.0)0.649
 Diabetic nephropathy57 (24.8)60 (27.4)0.591
 Other36 (15.7)36 (16.4)0.898
Urban-rural
 Rural34 (14.8)35 (16.0)
 Urban196 (85.2)184 (84.0)0.794
SIMD
 Least deprived171 (74.4)154 (70.3)
 Most deprived59 (25.7)65 (29.7)0.344
Era of stroke
 2005−200654 (23.5)88 (40.2)
 2007−200850 (21.7)44 (20.1)
 2009−201043 (18.7)48 (21.9)
 2011−201383 (36.1)39 (17.8)<0.001
Medical history
 Atrial fibrillation21 (9.1)30 (13.7)0.139
 Ischemic heart disease81 (35.2)86 (39.3)0.381
 Previous stroke20 (8.7)24 (11.0)0.432
 Diabetes90 (39.1)90 (41.1)0.701
 Hypercholesterolemia41 (17.8)34 (15.5)0.530
 Obesity15 (6.5)14 (6.4)1.000
 HBP171 (74.5)164 (74.9)0.914
Clinical variables, median (IQR)
 Systolic BP, mm Hg146.0 (30.0)141.0 (28.8)0.475
 Diastolic BP, mm Hg69.8 (22.0)68.5 (17.5)0.894
 Weight, kg68.4 (28.0)71.8 (23.1)0.213
Laboratory variables, median (IQR)
 Hemoglobin, g/l11.5 (1.8)11.4 (1.7)0.825
 Albumin, mmol/l36.0 (7.0)37.8 (6.0)0.171
 Serum phosphate, mmol/l1.45 (0.61)1.48 (0.62)0.449
 Adjusted calcium, mmol/l2.33 (0.2)2.35 (0.2)0.220
 ESA use
Death at follow-up191 (83.0)205 (93.6)<0.001

ESA, erythropoietin-stimulating agent; BP, blood pressure; HBP, high blood pressure; IQR, interquartile range; SIMD, Scottish Index of Multiple Deprivation; SMR01, Scottish Morbidity Records 01; SSCA, Scottish Stroke Care Audit.

Data are presented as no. (%).

Baseline demographics of all end-stage renal disease patients with stroke, split by source of diagnosis ESA, erythropoietin-stimulating agent; BP, blood pressure; HBP, high blood pressure; IQR, interquartile range; SIMD, Scottish Index of Multiple Deprivation; SMR01, Scottish Morbidity Records 01; SSCA, Scottish Stroke Care Audit. Data are presented as no. (%).

Demographics in ESRD: Stroke Versus No Stroke

In all individuals with ESRD, there were differences between those who experienced stroke and those who did not (Table 2). Individuals with stroke were older at commencing RRT, more likely to have atrial fibrillation, a history of stroke, and diabetes. In the dialysis group, previous ischemic heart disease was not associated with stroke, whereas higher serum phosphate was associated with stroke. In the transplantation group, the inverse was true; previous ischemic heart disease and lower serum phosphate were associated with stroke. Further details are outlined in Supplementary Tables S4 and S5.
Table 2

Baseline demographics of all end-stage renal disease patients, no stroke versus stroke

VariableNo stroke (n = 8271)Stroke (n = 486)P value
Age at first RRT, yr, median (IQR)56.4 (30.6)66.3 (19.3)<0.0001
Sex (%)
 Female3494 (41.7)221 (45.5)
 Male4893 (58.3)265 (54.5)0.098
Primary renal diagnosis group
 Glomuleronephritis1532 (18.5)70 (14.4)0.022
 Interstitial disease2205 (26.7)102 (21.0)0.006
 Multisystem1680 (20.3)114 (23.5)0.105
 Diabetic nephropathy1463 (17.7)122 (25.1)<0.0001
 Other1379 (16.7)78 (16.1)0.754
 Missing12 (0.1)0
Urban-rural
 Rural1380 (16.7)75 (15.4)
 Urban6891 (83.3)411 (84.6)0.491
SIMD
 Least deprived6129 (74.1)356 (73.3)
 Most deprived2142 (25.9)130 (26.8)0.670
Medical history
 Atrial fibrillation502 (6.1)52 (10.7)<0.001
 Ischemic heart disease2519 (30.5)176 (36.2)0.012
 Stroke272 (3.3)48 (9.9)<0.001
 Diabetes2468 (29.8)193 (39.7)<0.001
 Hypercholesterolemia1053 (12.7)80 (16.5)0.022
 Obesity464 (5.6)31 (6.4)0.480
 HBP5894 (71.3)361 (74.3)0.233
Clinical variables, median (IQR)
 Systolic BP, mm Hg138 (29.0)142 (30.0)<0.001
 Diastolic BP, mm Hg72 (18.0)69 (20.0)0.077
 Weight, kg72.7 (23.0)70.3 (25.6)0.008
Laboratory variables
 Hemoglobin, g/l11.7 (1.9)11.45 (1.5)<0.001
 Albumin, mmol/l38.0 (7.0)37.0 (7.0)<0.001
 Serum phosphate, mmol/l1.35 (0.6)1.46 (0.6)<0.001
 Adjusted calcium, mmol/l2.37 (0.2)2.35 (0.2)0.004
 ESA use4873 (58.9)268 (55.1)0.107
Death at follow-up4188 (50.6)433 (89.1)<0.001

ESA, erythropoietin-stimulating agent; BP, blood pressure; HBP, high blood pressure; IQR, interquartile range; RRT, renal replacement therapy; SIMD, Scottish Index of Multiple Deprivation.

Data are presented as no. (%).

Baseline demographics of all end-stage renal disease patients, no stroke versus stroke ESA, erythropoietin-stimulating agent; BP, blood pressure; HBP, high blood pressure; IQR, interquartile range; RRT, renal replacement therapy; SIMD, Scottish Index of Multiple Deprivation. Data are presented as no. (%).

Demographics: SSCA Stroke in the ESRD Population Versus SSCA Stroke in the Non-ESRD Population

We identified 61,367 individuals registered in the SSCA with stroke during our study period. A total of 280 (0.5%) individuals in the SSCA data set were on RRT for ESRD. Compared with the background population, individuals with ESRD developed stroke at a younger age, and had a greater prevalence of previous ischemic heart disease, hypertension, and diabetes (Table 3). Similar results were found in individuals on dialysis (Table 4). In the renal transplantation population, there were differences in age, sex, hypertension, and diabetes status (Table 5). PSM removed all demographic differences (Table 3, Table 4, Table 5).
Table 3

Demographics, presentation, management, and outcomes after stroke from the Scottish Stroke Care Audit showing data before and after propensity score matching for all patients with end-stage renal disease

VariableNon-ESRD population (n = 61,087)ESRD population (n = 280)Standardized differencea/P valuePropensity-matched non-ESRD population (n = 1,395)Propensity-matched renal population (n = 279)Standardized differencea/P value
Patient demographics
 Age at stroke, yr, median (IQR)76 (17.0)71 (16.0)−0.4870 (17.0)70 (17.0)−0.01
 Female31,368 (51.4)140 (50.0)−0.03713 (51.1)139 (49.8)−0.03
 Rural10,015 (16.4)41 (14.6)−0.05187 (13.4)41 (14.7)0.04
 Deprived29,709 (48.6)138 (49.3)0.01713 (51.1)138 (49.5)−0.03
 Previous AF5019 (8.2)26 (9.3)0.03102 (7.3)26 (9.3)0.07
 Previous CeVD3555 (5.8)27 (9.6)0.14111 (8.0)26 (9.3)0.05
 Previous IHD12,025 (19.7)97 (34.6)0.33486 (34.8)96 (34.4)−0.01
 Previous hypertension25,818 (42.3)208 (74.3)0.661073 (76.9)207 (74.2)−0.06
 Previous diabetes8536 (14.0)113 (40.4)0.61531 (38.1)112 (40.1)0.04
Case mix
 Independent in ADLs before admission47,184 (77.2)179 (63.9)<0.00011096 (78.6)178 (63.8)<0.0001
 Missing5109 (8.4)37 (13.2)134 (9.6)37 (13.3)
 Living alone before admission22,065 (36.1)64 (22.9)<0.0001430 (30.8)64 (22.9)0.025
 Missing4453 (7.3)36 (12.9)124 (8.9)36 (12.9)
 Talking at first assessment42,795 (70.1)196 (70.0)0.3861020 (73.1)195 (69.9)0.678
 Missing3707 (6.1)26 (9.3)93 (6.7)26 (9.3)
 Orientated at first assessment35,846 (58.7)160 (57.1)0.789895 (64.2)159 (57.0)0.094
 Missing5325 (8.7)35 (12.5)128 (9.2)35 (12.5)
 Able to lift arms at first assessment35,622 (58.3)178 (63.6)0.013833 (59.7)178 (63.8)0.092
 Missing4817 (7.9)29 (10.4)123 (8.8)29 (10.4)
 Able to walk on first assessment23,732 (38.9)95 (33.9)0.197561 (40.2)95 (34.1)0.091
 Missing5529 (9.1)34 (12.1)141 (10.1)34 (12.2)
Index stroke
 Ischemic51,606 (84.5)255 (91.1)1186 (85.0)245 (91.0)
 Hemorrhagic6954 (11.4)23 (8.2)0.063140 (10.0)23 (8.2)0.277
 Missing2527 (4.1)2 (0.7)69 (5.0)2 (0.7)
Admission source
 Acute hospital1984 (3.3)22 (7.9)<0.00131 (2.2)21 (7.5)<0.0001
 Sheltered/care home2758 (4.5)2 (0.7)<0.00141 (2.9)2 (0.7)0.035
 Home54,613 (89.4)240 (85.7)0.2501277 (91.5)240 (86.0)0.050
 Rehab/other904 (1.5)7 (2.5)0.13331 (2.2)7 (2.5)0.661
 Missing828 (1.4)9 (3.2)15 (1.1)9 (3.2)
Management
 Admitted to stroke unit47,619 (78.0)189 (67.5)0.0021110 (79.6)188 (67.4)<0.001
 Missing1415 (2.3)16 (5.7)24 (1.7)16 (5.7)
 Thrombolysis: IS only2487 (4.8)10 (3.9)0.64954 (4.6)10 (3.9)0.863
 Missing25,009 (40.9)126 (45)560 (40.1)125 (44.8)
 Aspirin: IS only43,194 (83.7)190 (74.5)<0.001991 (83.6)190 (74.8)0.002
 Missing601 (1.0)4 (1.4)13 (0.9)4 (1.4)
 Swallow screen48,692 (79.7)214 (76.4)0.1911098 (78.7)213 (76.3)0.433
 Missing2519 (4.1)13 (4.6)59 (4.2)13 (4.7)
 Brain imaging59,680 (97.7)278 (99.3)0.2571365 (97.9)277 (99.3)0.754
 Missing284 (0.5)014 (1.0)0
Duration of admission (IQR)13 (37.0)16 (38.0)0.21112 (33.0)16 (38.0)0.079
Discharge destination
 NHS bed3969 (6.5)42 (15.0)<0.000166 (4.7)42 (15.1)<0.0001
 Care home6390 (10.5)15 (5.4)0.003100 (7.2)15 (5.4)0.302
 Home/sheltered39,125 (64.1)153 (54.6)<0.001979 (70.2)152 (54.5)<0.0001
 Other782 (1.3)4 (1.4)0.78625 (1.8)4 (1.4)0.806
 Died9694 (15.9)62 (22.1)0.007188 (13.5)62 (22.2)0.001
 Missing1127 (1.8)4 (1.4)37 (2.7)4 (1.4)
Death at follow-up33,169 (54.3)229 (81.8)<0.0001676 (48.5)228 (81.7)<0.0001

ADL, activities of daily living; AF, atrial fibrillation; CeVD, Cerebrovascular Disease; IHD, ischemic heart disease; IQR, interquartile range; IS, ischemic stroke; NHS, National Health Service.

Data are presented as no. (%).

Standardized difference: difference in means or proportions divided by SE; imbalance defined as absolute values >0.20.

Table 4

Demographics, presentation, management, and outcomes after stroke form the Scottish Stroke Care Audit showing data before and after propensity score matching for individuals on dialysis for end-stage renal disease.

VariableNon-ESRD population (n = 61,087)Dialysis population (n = 224)Standardized differencea/P valuePropensity-matched non-ESRD population (n = 1115)Propensity-matched dialysis population (n = 223)Standardized differencea/P value
Patient demographics
 Age at stroke, yr (IQR)76 (17.0)72 (16.0)−0.3773 (15.0)72 (16.0)−0.09
 Female31,368 (51.4)119 (53.1)0.04613 (55.0)118 (52.9)−0.04
 Rural10,015 (16.4)35 (15.6)−0.02169 (15.2)35 (15.7)0.01
 Deprived29,709 (48.6)108 (48.2)−0.01542 (48.6)108 (48.4)0.00
 Previous AF5019 (8.2)22 (9.8)0.05107 (9.6)22 (9.9)0.01
 Previous CeVD3555 (5.8)22 (9.8)0.1488 (7.9)21 (9.4)0.05
 Previous IH12,025 (19.7)82 (36.6)0.37435 (39.0)81 (36.3)−0.06
 Previous hypertension25,818 (42.3)167 (74.6)0.66872 (78.2)166 (74.4)−0.09
 Previous diabetes8536 (14.0)93 (41.5)0.63445 (39.9)92 (41.3)0.03
Case mix
 Independent in ADLs before admission47,184 (77.2)138 (61.6)<0.0001886 (77.7)137 (61.4)<0.0001
 Missing5109 (8.4)28 (12.5)118 (10.6)28 (12.6)
 Living alone before admission22,065 (36.1)52 (23.2)<0.001346 (31.0)52 (23.3)0.046
 Missing4453 (7.3)27 (12.1)95 (8.5)27 (12.1)
 Talking at first assessment42,795 (70.1)159 (71.0)0.377797 (71.5)158 (70.9)0.856
 Missing3707 (6.1)19 (8.5)74 (6.6)19 (8.5)
 Orientated at first assessment35,846 (58.7)13 (58.0)0.824686 (61.5)129 (57.9)0.508
 Missing5325 (8.7)25 (11.2)101 (9.1)25 (11.2)
 Able to lift arms at first assessment35,622 (58.3)141 (63.0)0.080650 (58.3)141 (63.2)0.125
 Missing4817 (7.9)21 (9.4)99 (8.9)21 (9.4)
 Able to walk on first assessment23,732 (38.9)69 (30.8)0.026420 (37.7)69 (30.9)0.068
 Missing5529 (9.1)26 (11.6)118 (10.6)26 (11.7)
Index stroke
 Ischemic51,606 (84.5)203 (90.6)947 (84.9)202 (90.6)
 Hemorrhagic6954 (11.4)19 (8.5)122 (10.9)19 (8.5)
 Missing2527 (4.1)2 (0.9)0.14546 (4.1)2 (0.9)0.239
Admission source
 Acute hospital1984 (3.3)22 (9.8)<0.000127 (2.4)21 (9.4)<0.0001
 Sheltered/care home2758 (4.5)2 (0.9)0.00530 (2.7)2 (0.9)0.147
 Home54613 (89.4)186 (83.0)0.0191020 (91.5)186 (83.4)0.001
 Rehab/Other904 (1.5)7 (3.1)0.04718 (1.6)7 (3.1)0.166
 Missing828 (1.4)7 (3.1)20 (1.8)7 (3.1)
Management
 Admitted to stroke unit49,619 (78.0)145 (64.7)<0.001888 (79.6)144 (64.6)<0.001
 Missing1415 (2.3)16 (7.1)27 (2.4)16 (7.2)
 Thrombolysis: IS only2487 (4.8)7 (3.5)0.49647 (5.0)7 (3.5)0.568
 Missing25,009 (40.9)100 (44.6)439 (39.4)99 (44.4)
 Aspirin: IS only43,194 (83.7)152 (74.9)0.002788 (83.2)152 (75.3)0.010
 Missing601 (1.0)3 (1.3)11 (1.0)3 (1.3)
 Swallow screen48,692 (79.7)173 (77.2)0.315903 (81.0)172 (77.1)0.229
 Missing2519 (4.1)9 (4.0)38 (3.4)9 (4.0)
 Brain imaging59,680 (97.7)222 (99.1)0.4501095 (98.2)221 (99.1)1.000
 Missing284 (0.5)06 (0.5)0
Duration of admission (IQR)13 (37.0)17 (39.0)0.10112 (36.0)17 (39.0)0.027
Discharge destination, n (%)
 NHS bed3969 (6.5)38 (17.0)<0.000153 (4.8)38 (17.0)<0.0001
 Care home6390 (10.5)14 (6.3)0.03797 (8.7)14 (6.3)0.287
 Home/sheltered39,125 (64.1)114 (50. 9)<0.0001765 (68.6)113 (50.7)<0.0001
 Other782 (1.3)4 (1.8)0.54119 (1.7)4 (1.8)1.000
 Died9694 (15.9)51 (22.7)0.008160 (14.4)51 (22.9)0.002
 Missing1127 (1.8)3 (1.3)21 (1.9)3 (1.3)
Death at end follow-up33,169 (54.3)192 (85.7)<0.0001590 (52.9)191 (85.7)<0.0001

ADL, activities of daily living; AF, atrial fibrillation; CeVD, Cerebrovascular Disease; IHD, ischemic heart disease; IQR, interquartile range; IS, ischemic stroke; NHS, National Health Service.

Data are presented as no. (%).

Standardized difference: difference in means or proportions divided by SE; imbalance defined as absolute values >0.20.

Table 5

Demographics, presentation, management, and outcomes after stroke from the Scottish Stroke Care Audit showing data before and after propensity score matching for individuals with a renal transplant

VariableNon-ESRD population (n = 61,087)Kidney transplant (RT) population (n = 56)Standardized differencea/P valuePropensity-matched non-ESRD population (n = 280)Propensity-matched RT population (n = 56)Standardized differencea/P value
Patient demographics
 Age, yr, median (IQR)76 (17.0)65.5 (15.0)−0.9966 (15)65.5 (15.0)−0.12
 Female31,368 (51.4)21 (37.5)−0.28101 (36.1)21 (37.5)0.03
 Rural10,015 (16.4)6 (10.7)−0.1722 (7.9)6 (10.7)0.10
 Deprived29,709 (48.6)30 (53.6)0.10156 (55.7)30 (53.6)−0.04
 Previous AF5019 (8.2)4 (7.1)−0.0512 (4.3)4 (7.1)0.12
 Previous CeVD3555 (5.8)5 (8.9)0.1127 (9.6)5 (8.9)−0.02
 Previous IHD12,025 (19.7)15 (26.8)0.1579 (28.2)15 (26.8)−0.03
 Previous hypertension25,818 (42.3)41 (73.2)0.63207 (73.9)41 (73.2)−0.02
 Prior diabetes8536 (14.0)20 (35.7)0.51101 (36.1)20 (35.7)−0.01
Case mix
 Independent in ADLs before admission47,184 (77.2)41 (73.2)0.692236 (84.3)41 (73.2)0.597
 Missing5109 (8.4)9 (16.1)19 (6.8)9 (16.1)
 Living alone before admission22,065 (36.1)12 (21.4)0.07285 (30.4)12 (21.4)0.397
 Missing4453 (7.3)9 (16.1)18 (6.4)9 (16.1)
 Talking at first assessment42795 (70.1)37 (66.1)1.000218 (77.9)37 (66.1)0.322
 Missing3707 (6.1)7 (12.5)14 (5.0)7 (12.5)
 Orientated at first assessment35,846 (58.7)30 (53.6)1.000194 (69.3)30 (53.6)0.214
 Missing5325 (8.7)10 (17.9)18 (6.4)10 (17.9)
 Able to lift arms at first assessment35,622 (58.3)37 (66.1)0.052187 (66.8)37 (66.1)0.486
 Missing4817 (7.9)8 (14.3)18 (6.4)8 (14.3)
 Able to walk on first assessment23,732 (38.9)26 (46.4)0.111128 (45.7)26 (46.4)0.638
 Missing5529 (9.1)8 (14.3)21 (7.5)8 (14.3)
Index stroke
 Ischemic51,606 (84.5)52 (92.9)242 (86.4)52 (92.9)
 Hemorrhagic6954 (11.4)4 (7.1)30 (10.7)4 (7.1)
 Missing2527 (4.1)00.4058 (2.9)00.477
Admission source
 Acute hospital1984 (3.3)00.42611 (3.9)00.223
 Sheltered/care home2758 (4.5)00.1808 (2.9)00.362
 Home54,613 (89.4)54 (96.4)0.009255 (91.1)54 (96.4)0.032
 Rehab/other904 (1.5)01.0002 (0.7)01.000
 Missing828 (1.4)2 (3.6)4 (1.4)2 (3.6)
Management
 Admitted to stroke unit47,619 (78.0)44 (78.6)0.868221 (78.9)44 (78.6)0.712
 Missing1415 (2.3)07 (2.5)0
 Thrombolysis: IS only2487 (4.8)3 (5.8)0.7318 (3.3)3 (5.8)0.407
 Missing25,009 (40.9)26 (46.4)119 (42.5)26 (46.4)
 Aspirin: IS only43,194 (83.7)38 (73.1)0.051200 (82.6)38 (73.1)0.157
 Missing601 (1.0)1 (1.8)3 (1.1)1 (1.8)
 Swallow screen48,692 (79.7)41 (73.2)0.457222 (79.3)41 (73.2)0.565
 Missing2519 (4.1)4 (7.1)9 (3.2)4 (7.1)
 Brain imaging59,680 (97.7)56 (100.0)0.629276 (98.6)56 (100)1.000
 Missing284 (0.5)04 (1.4)0
Duration of admission (IQR)13 (37)11 (32)0.68311 (22)11 (32)0.541
Discharge destination
 NHS bed3969 (6.5)4 (7.1)0.78416 (5.7)4 (7.1)0.756
 Care home6390 (10.5)1 (1.8)0.02715 (5.4)1 (1.8)0.488
 Home/sheltered39,125 (64.1)39 (69.6)0.479214 (76.4)39 (69.6)0.292
 Other782 (1.3)01.0003 (1.1)01.000
 Died9694 (15.9)11 (19.6)0.46226 (9.3)11 (19.6)0.034
 Missing1127 (1.8)1 (1.8)6 (2.1)1 (1.8)
Death at follow−up33,169 (54.3)37 (66.1)0.082117 (41.8)37 (66.1)0.001

ADL, activities of daily living; AF, atrial fibrillation; CeVD, Cerebrovascular Disease; IHD, ischemic heart disease; IQR, interquartile range; IS, ischemic stroke; NHS, National Health Service.

Standardized difference: difference in means or proportions divided by SE; imbalance defined as absolute values >0.20.

Demographics, presentation, management, and outcomes after stroke from the Scottish Stroke Care Audit showing data before and after propensity score matching for all patients with end-stage renal disease ADL, activities of daily living; AF, atrial fibrillation; CeVD, Cerebrovascular Disease; IHD, ischemic heart disease; IQR, interquartile range; IS, ischemic stroke; NHS, National Health Service. Data are presented as no. (%). Standardized difference: difference in means or proportions divided by SE; imbalance defined as absolute values >0.20. Demographics, presentation, management, and outcomes after stroke form the Scottish Stroke Care Audit showing data before and after propensity score matching for individuals on dialysis for end-stage renal disease. ADL, activities of daily living; AF, atrial fibrillation; CeVD, Cerebrovascular Disease; IHD, ischemic heart disease; IQR, interquartile range; IS, ischemic stroke; NHS, National Health Service. Data are presented as no. (%). Standardized difference: difference in means or proportions divided by SE; imbalance defined as absolute values >0.20. Demographics, presentation, management, and outcomes after stroke from the Scottish Stroke Care Audit showing data before and after propensity score matching for individuals with a renal transplant ADL, activities of daily living; AF, atrial fibrillation; CeVD, Cerebrovascular Disease; IHD, ischemic heart disease; IQR, interquartile range; IS, ischemic stroke; NHS, National Health Service. Standardized difference: difference in means or proportions divided by SE; imbalance defined as absolute values >0.20.

Output After PSM: Case Mix

Individuals with ESRD were less likely to be independent in activities of daily living (63.8% vs. 78.6%; P < 0.0001) and less likely to be living alone (22.9% vs. 30.8%; P = 0.025) before admission. There were similar results found in individuals on dialysis, but there were no significant differences between individuals with a kidney transplant and the non-ESRD stroke population (Table 3, Table 4, Table 5).

Output After PSM: Admission Source

Individuals with ESRD and individuals treated with dialysis were more likely to present with stroke from an acute hospital rather than from home (7.5% vs. 2.2%; P < 0.0001 and 9.4% vs. 2.4%; P < 0.0001, respectively). Transplant recipients were more likely to be admitted from home (96.4% vs. 91.1%; P = 0.032) compared with the non-ESRD stroke population (Table 3, Table 4, Table 5).

Output After PSM: Stroke Care and Audit Standards

Individuals with ESRD and individuals treated with dialysis were less likely to be managed on an acute stroke unit during their admission (67.4% vs. 79.6%; P < 0.001 and 64.6% vs. 79.6%; P < 0.001, respectively) and less likely to receive aspirin (74.8% vs. 83.6%; P = 0.002 and 75.3% vs. 83.2%; P = 0.01, respectively). There were no differences in management of transplantation recipients compared with the non-ESRD stroke population (Table 3, Table 4, Table 5). Individuals on dialysis were less likely to be admitted to a stroke unit on day 0 or 1 (43.5% vs. 62.6%; P = 0.005), less likely to have a swallow screen within the first 24 hours (66.4% vs. 74.1%; P = 0.017), and less likely to receive thrombolysis within 60 minutes (1.5% vs. 3.9%; P = 0.016). These measures did not differ in kidney transplantation recipients (Supplementary Tables S6–S8).

PSM: Discharge Destination

Individuals with ESRD and individuals on dialysis were more likely to remain in an National Health Service inpatient bed (15.1% vs. 4.7%; P < 0.0001 and 17.0% vs. 4.8%; P < 0.0001, respectively) and were less likely to be discharged to home or to a sheltered accommodation (54.5% vs. 70.2%; P < 0.0001 and 50.7% vs. 68.6%; P < 0.0001). This association was not present in individuals with a kidney transplant. In both dialysis and kidney transplant patients, in-hospital mortality was almost double the rate demonstrated in individuals without ESRD (dialysis: 22.9% vs. 14.4%; P = 0.002; transplant: 19.6% vs. 9.3%; P = 0.034).

ESRD Mortality After Stroke

At end of follow-up, 4621 (52.8%) individuals with ESRD had died. Death was more likely in individuals who were older, who had high cardiovascular comorbidity burden, and who experienced stroke during follow-up. Further demographics are presented in Table 6.
Table 6

Baseline demographics of all end-stage renal disease patients, alive versus dead at end of follow-up

VariableAlive (n = 4136)Dead (n = 4621)P value
Age at first RRT, yr, median (IQR)44.6 (27.0)67 (20.8)<0.0001
Sex
 Female1743 (42.1)1932 (41.8)
 Male2393 (57.9)2689 (58.2)0.761
Primary renal diagnosis group
 Missing1 (0.02)11 (0.2)
 Glomuleronephritis989 (23.9)613 (13.3)<0.0001
 Interstitial disease1403 (33.9)904 (19.6)<0.0001
 Multisystem613 (14.8)1181 (25.6)<0.0001
 Diabetic nephropathy540 (13.1)1045 (22.6)<0.0001
 Other590 (14.3)867 (18.8)<0.0001
Urban-rural
 Rural722 (17.5)733 (15.9)
 Urban3414 (82.5)3888 (84.1)0.047
SIM
 Least deprived3080 (74.5)3405 (73.7)
 Most deprived1056 (25.5)1216 (26.3)0.407
Medical history
 Atrial fibrillation76 (1.8)478 (10.3)<0.0001
 Ischemic heart disease743 (18.0)1952 (42.2)<0.0001
 Stroke60 (1.5)260 (5.6)<0.0001
 Diabetes935 (22.6)1726 (37.4)<0.0001
 Hypercholesterolemia423 (10.2)710 (15.4)<0.0001
 Obesity201 (4.9)294 (6.4)0.004
 HBP2887 (69.8)3368 (72.9)0.017
Clinical variables, median (IQR)
 Systolic BP, mm Hg138.0 (27.0)138.5 (31.5)0.755
 Diastolic BP, mm Hg75.0 (17.0)69.0 (19.0)<0.0001
 Weight, kg75.2 (23.0)70.3 (22.3)<0.0001
Laboratory variables
 Hemoglobin, g/l12 (2.0)11.3 (1.8)<0.0001
 Albumin, mmol/l39 (6.0)36 (7.0)<0.0001
 Serum phosphate, mmol/l1.21 (0.6)1.45 (0.6)<0.0001
 Adjusted calcium, mmol/l2.38 (0.2)2.36 (0.2)<0.0001
 ESA use
Stroke during study period53 (1.3)433 (9.4)<0.0001

ESA, erythropoietin-stimulating agent; BP, blood pressure; HBP, high blood pressure; IQR, interquartile range; RRT, renal replacement therapy; SIMD, Scottish Index of Multiple Deprivation.

Data are presented as no. (%).

Baseline demographics of all end-stage renal disease patients, alive versus dead at end of follow-up ESA, erythropoietin-stimulating agent; BP, blood pressure; HBP, high blood pressure; IQR, interquartile range; RRT, renal replacement therapy; SIMD, Scottish Index of Multiple Deprivation. Data are presented as no. (%). A total of 229 (81.8%) of the 280 individuals with ESRD who experienced stroke died compared with 33,169 (54.3%) of 61,087 individuals in the general stroke population. The higher mortality rate remained after PSM (85.7% vs. 52.9% for dialysis; P < 0.0001 and 66.1% vs. 41.8% for transplant; P = 0.001) (Tables 4 and 5). Median survival (IQR) after stroke was 0.8 (2.1) years in individuals on dialysis, 2.5 (3.8) years in individuals with a kidney transplant, and 3.1 (4.4) years in the non-ESRD stroke population (P < 0.0001) (Figure 1 and Supplementary Figure S3, demonstrating split by RRT modality).
Figure 1

Kaplan-Meier estimator survival curves demonstrating time to death after stroke in the matched population without end-stage renal disease (ESRD), transplant recipients. and dialysis patients. Log-rank test; P < 0.0001.

Kaplan-Meier estimator survival curves demonstrating time to death after stroke in the matched population without end-stage renal disease (ESRD), transplant recipients. and dialysis patients. Log-rank test; P < 0.0001. When we assessed all stroke episodes in both ESRD and non-ESRD populations, there was demonstrably lower survival in individuals with ESRD than those without ESRD. Furthermore, the presence of first recorded stroke episode during follow-up within the SMR01 was associated with lower survival than those recorded within the SSCA (Figure 2).
Figure 2

Kaplan-Meier survival curves demonstrating time to death after following stroke in both end-stage renal disease (ESRD) and non-ESRD populations, split by source of stroke diagnosis: non-ESRD Scottish Stroke Care Audit (SSCA), non-ESRD Scottish Morbidity Records 01 (SMR01), ESRD population SSCA, and ESRD population SMR01. Log-rank test; P < 0.0001.

Kaplan-Meier survival curves demonstrating time to death after following stroke in both end-stage renal disease (ESRD) and non-ESRD populations, split by source of stroke diagnosis: non-ESRD Scottish Stroke Care Audit (SSCA), non-ESRD Scottish Morbidity Records 01 (SMR01), ESRD population SSCA, and ESRD population SMR01. Log-rank test; P < 0.0001. In individuals with ESRD alone, 157 (35.0%) patients with a first recorded stroke were admitted to a stroke unit. At follow-up, mortality was lower in those admitted to a stroke unit (82.8% vs. 91.1%; P = 0.014). On multivariable analysis, admission to a stroke unit was associated with lower risk of death (hazard ratio: 0.68; 95% confidence interval: 0.55−0.84; P < 0.001) (Figure 3 and Supplementary Table S9).
Figure 3

Kaplan-Meier survival curves demonstrating time to death after stroke in patients with end-stage renal disease and the effect of admission to an acute stroke unit (ASU). Log-rank test P < 0.0001.

Kaplan-Meier survival curves demonstrating time to death after stroke in patients with end-stage renal disease and the effect of admission to an acute stroke unit (ASU). Log-rank test P < 0.0001.

Discussion

In this population-based record linkage cohort study we demonstrated that incidence of stroke in ESRD is high and higher in individuals receiving dialysis compared with kidney transplant recipients. We found individuals with ESRD who experienced stroke were more functionally dependent at presentation, there were differences in delivery of stroke care to individuals with ESRD, and in-hospital death from stroke was higher. These findings suggest that provision of stroke care for individuals with ESRD needs urgent review. The stroke rate of 25.3 and 4.5 per 1000 patient-years in individuals on dialysis or transplant recipients, respectively, is in keeping with previous published reports.8, 20, 22, 23 During the same period, the crude incidence rate for cerebrovascular disease in Scotland was 2.4 per 1000 patient-years, which demonstrated a 10-fold increase in stroke incidence in individuals who received dialysis. In real-world terms, in our renal unit, with prevalent population of approximately 650 dialysis recipients, this equated to 1 stroke every 22 days or, nationally, 1 stroke per week.

Stroke Incidence and Presentation

Individuals on dialysis were functionally more dependent at presentation than their matched non-ESRD stroke population cohort. Functional dependence is common in ESRD and is an independent predictor of mortality. Patients who received dialysis were more likely to be admitted from an acute hospital than home. There were possible explanations for this. Primarily, there is an increased likelihood of hospitalization with ESRD but also a temporal relationship between dialysis itself and stroke. In one single-center study, 39.5% of infarctions and 34.7% hemorrhages occurred during or within 30 minutes of completing dialysis. It is likely that such strokes would initially be referred to nephrology.

Inequalities in Care

As well as being less likely to be managed in acute stroke units, individuals with ESRD treated with dialysis were less likely to undergo a swallow test within the first 24 hours, less likely to receive aspirin on arrival to hospital, and less likely to receive prompt thrombolytic therapy. Interestingly, this pattern of care was not seen in renal transplant recipients. Differences in care after myocardial infarction in ESRD are previously demonstrated, but these differences were attributed to a lack of an accurate diagnosis at first assessment due to higher rates of atypical symptoms and electrocardiographic changes. In our cohort, presenting symptoms were similar between groups; therefore, so we believe delayed recognition of stroke did not explain the differences. It is possible that practical considerations surrounding need for dialysis make stroke unit care impractical or unattractive. In a survey of nephrologists it was felt that adverse effects of dialysis schedules, coupled with lack of stroke unit care might negatively affect recovery and would require future attention. An alternate explanation was that specialist stroke units might feel uncomfortable caring for dialysis patients and elect not to transfer care. Only 280 of 486 strokes that occurred in individuals with ESRD were included in the SSCA data set. It is believed that the SSCA most accurately represents the number of strokes occurring in Scotland. It is acknowledged that omission of strokes from the SSCA can occur if the patient was in hospital at the time of stroke or was not referred promptly to stroke services. Such a high number of strokes not recorded in the SSCA was unexpected and suggested substantial inequality in access to gold standard stroke care for individuals with ESRD. A recent paper that addressed selection bias after stroke demonstrated consistent improvement up to 1 year after stroke from use of stroke units. We explored this discrepancy by examining the effects of admission to a stroke unit as a marker of optimal stroke care. Individuals with ESRD admitted to a stroke unit had a significantly lower mortality rate at follow-up than those who were not admitted. It must be acknowledged this might be in part related to selection bias at the time of stroke; those more severely affected at presentation might not be referred onward.

Discrepancies in Mortality

Mortality after stroke is declining in general population studies, but we found striking differences in mortality rates — both during stroke admission and on longer follow-up. This extended to individuals with ESRD and a kidney transplant who were twice as likely to die on their initial admission and had higher mortality rates at follow-up. Because our matching process controlled for hypertension, diabetes, and ischemic heart disease, an accrued risk specific to CKD not reversed by transplantation seems a likely explanation. This is an important finding because transplant recipients with normal range serum creatinine could be overlooked as having a lower risk. Unfortunately, creatinine values were not available in our non-ESRD population data. Finally, we detected significant differences in survival based on diagnosis source; higher survival occurred in individuals diagnosed via SSCA compared with individuals in the SMR01, and there was higher survival in those admitted to a stroke unit. These findings support the conclusion that specialist stroke care was associated with a lower mortality rate in individuals with ESRD. Although this may be related to therapeutic nihilism in cases of more severe stroke, we could not provide data to support this. Therefore, serious consideration must be paid to the merits of managing stroke on a renal ward for reasons of dialysis practicalities alone.

Strengths and Limitations

Linkage of national data sets provided a large population with unique results that demonstrated issues relevant to patient care. Our main strengths included large numbers of patients in both ESRD and stroke populations. Scotland is broadly representative of both European nephrology and stroke care in terms of patient demographics and outcomes for both conditions.31, 32 Furthermore, the granularity of data allowed description of the stroke pathway from presentation to discharge, use of death records allowed a follow-up period, and since 2005, both the SRR and SSCA have been all-inclusive data sets. We supported complete capture by accessing the SMR01 data set. Despite these strengths, we acknowledge limitations. First, all data were retrospective, and therefore, we could not prove causation, only describe associations. Because it was not feasible to study the primary outcome of our study—impact of ESRD on outcomes after stroke—in a randomized fashion, we addressed the retrospective nature of the data by performing PSM. Second, missing data limited the ability to fully exclude other factors that influenced outcome. For instance, we lacked markers of stroke severity (e.g., National Institutes of Health Stroke Scale) because this was only recorded when thrombolysis was used. Finally, discrepancies in survival after stroke split by diagnosis source warrants attention. Selection bias could result in frailer, sicker patients bypassing the stroke unit (and omission from the SSCA) following deterioration on dialysis. Nonspecialist input might result in misdiagnosis. However, internal validation of SMR01 coding confirmed the approximately 90% accuracy rate, making this unlikely.

Conclusions

Stroke is common in individuals with ESRD with poor outcomes. Individuals on dialysis are functionally more dependent at presentation and are less likely to be managed on a stroke unit. Individuals with a renal transplantation are similar at presentation and provided with equivalent care to the general population, but retain a significantly higher mortality rate. ESRD should not exclude individuals from ideal care after stroke, and efforts should be made to deliver such care to all.

Disclosure

All the authors declared no competing interests.
  29 in total

Review 1.  Epidemiology of cardiovascular disease in chronic renal disease.

Authors:  R N Foley; P S Parfrey; M J Sarnak
Journal:  J Am Soc Nephrol       Date:  1998-12       Impact factor: 10.121

2.  Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis.

Authors:  Mitesh Shah; Meytal Avgil Tsadok; Cynthia A Jackevicius; Vidal Essebag; Mark J Eisenberg; Elham Rahme; Karin H Humphries; Jack V Tu; Hassan Behlouli; Helen Guo; Louise Pilote
Journal:  Circulation       Date:  2014-01-22       Impact factor: 29.690

3.  Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients.

Authors:  G Ocak; K J van Stralen; F R Rosendaal; M Verduijn; P Ravani; R Palsson; T Leivestad; A J Hoitsma; M Ferrer-Alamar; P Finne; J De Meester; C Wanner; F W Dekker; K J Jager
Journal:  J Thromb Haemost       Date:  2012-12       Impact factor: 5.824

4.  Stroke in patients on maintenance hemodialysis: a 22-year single-center study.

Authors:  Kazunori Toyoda; Kenichiro Fujii; Satoru Fujimi; Yasuhiro Kumai; Hirohito Tsuchimochi; Setsuro Ibayashi; Mitsuo Iida
Journal:  Am J Kidney Dis       Date:  2005-06       Impact factor: 8.860

5.  Prevalence and correlates of functional dependence among maintenance dialysis patients.

Authors:  Niall T Kavanagh; Brigitte Schiller; Anjali B Saxena; I-Chun Thomas; Manjula Kurella Tamura
Journal:  Hemodial Int       Date:  2015-03-02       Impact factor: 1.812

6.  Elevated risk of stroke among patients with end-stage renal disease.

Authors:  Stephen L Seliger; Daniel L Gillen; W T Longstreth; Bryan Kestenbaum; Catherine O Stehman-Breen
Journal:  Kidney Int       Date:  2003-08       Impact factor: 10.612

7.  Factors influencing withdrawal from dialysis: a national registry study.

Authors:  Mark D Findlay; Ken Donaldson; Arthur Doyle; Jonathan G Fox; Izhar Khan; Jackie McDonald; Wendy Metcalfe; Robert K Peel; Ilona Shilliday; Elaine Spalding; Graham A Stewart; Jamie P Traynor; Bruce Mackinnon
Journal:  Nephrol Dial Transplant       Date:  2016-04-21       Impact factor: 5.992

Review 8.  Effects of hemodialysis on cardiac function.

Authors:  Christopher W McIntyre
Journal:  Kidney Int       Date:  2009-06-10       Impact factor: 10.612

9.  Functional Dependence and Mortality in the International Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  S Vanita Jassal; Angelo Karaboyas; Leah A Comment; Brian A Bieber; Hal Morgenstern; Ananda Sen; Brenda W Gillespie; Patricia De Sequera; Mark R Marshall; Shunichi Fukuhara; Bruce M Robinson; Ronald L Pisoni; Francesca Tentori
Journal:  Am J Kidney Dis       Date:  2015-11-21       Impact factor: 8.860

10.  Risk Factors of Ischemic Stroke and Subsequent Outcome in Patients Receiving Hemodialysis.

Authors:  Mark D Findlay; Peter C Thomson; Rachael L Fulton; Marit D Solbu; Alan G Jardine; Rajan K Patel; Kathryn K Stevens; Colin C Geddes; Jesse Dawson; Patrick B Mark
Journal:  Stroke       Date:  2015-07-30       Impact factor: 7.914

View more
  4 in total

1.  A Dynamic Nomogram to Identify Patients at High Risk of Poor Outcome in Stroke Patients with Chronic Kidney Disease.

Authors:  Fusang Wang; Xiaohan Zheng; Juan Zhang; Fuping Jiang; Nihong Chen; Mengyi Xu; Yuezhang Wu; Junshan Zhou; Xiaoli Cui; Jianjun Zou
Journal:  Clin Interv Aging       Date:  2022-05-10       Impact factor: 4.458

2.  Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.

Authors:  Patrick B Mark; Pardeep S Jhund; Matthew R Walters; Mark C Petrie; Albert Power; Claire White; Michele Robertson; Eugene Connolly; Stefan D Anker; Sunil Bhandari; Kenneth Farrington; Philip A Kalra; Charles R V Tomson; David C Wheeler; Christopher G Winearls; John J V McMurray; Iain C Macdougall; Ian Ford
Journal:  Kidney360       Date:  2021-09-16

3.  Impact of prior stroke on major clinical outcome in chronic kidney disease: the Salford kidney cohort study.

Authors:  James Tollitt; Aghogho Odudu; Emma Flanagan; Rajkumar Chinnadurai; Craig Smith; Philip A Kalra
Journal:  BMC Nephrol       Date:  2019-11-27       Impact factor: 2.388

4.  Linking disease registries and nationwide healthcare administrative databases: the French renal epidemiology and information network (REIN) insight.

Authors:  Maxime Raffray; Sahar Bayat; Mathilde Lassalle; Cécile Couchoud
Journal:  BMC Nephrol       Date:  2020-01-28       Impact factor: 2.585

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.